Healthy Clinical Trial
Official title:
Persistence of Epstein-Barr Virus in Vivo
This study will examine the effects of long-term antiviral therapy with valaciclovir
(Valtrex) on Epstein-Barr virus infection. This virus infects more than 95 percent of people
in the United States. Most are infected in childhood, have no symptoms, and are unaware of
their infection. People infected as adolescents or adults may develop infectious
mononucleosis, which usually resolves completely. Once infected, most people shed the virus
from their throat occasionally, and all carry the virus in their white blood cells for life.
This study will determine whether the amount of virus in the blood declines or disappears
with long-term valaciclovir treatment.
Normal volunteers who are not taking any antiviral medicines and patients enrolled in NIH's
protocol no. 97-I-0168 (Evaluation of Valaciclovir for Prevention of Herpes Simplex Virus
Transmission) or Glaxo-Wellcome protocol HS2AB 3009 at collaborating centers may be eligible
for this study. Patients in the multi-center study must be about to start valaciclovir
therapy for at least 1 year. All candidates must be 18 years of age or older.
Study participants will be seen in clinic for about 1 hour every 3 months for a year. During
these visits, they will provide information about the medicines they are taking, gargle twice
with salt water and spit the fluid into a tube, and have blood drawn (no more than 8
teaspoons each visit). The blood and gargled fluid will be tested for the amount of
Epstein-Barr virus and antibodies to the virus. (Blood samples will also be tested for HLA
type in order to do immunologic studies in the laboratory. HLA is a marker of the immune
system that is similar to blood-typing testing.)
The results in people taking valaciclovir will be compared with those in people not taking
the drug. People whose results show the virus has disappeared from the body will continue to
be followed twice a year for 5 years with the blood and gargling tests to continue to look
for evidence of virus. Also, people who develop symptoms resembling mononucleosis (e.g.,
enlarged lymph nodes with fever and sore throat) will be asked to have their blood tested for
the virus.
Epstein-Barr virus (EBV) is the cause of heterophile-positive infectious mononucleosis. After primary EBV infection, the virus persists in resting memory B lymphocytes and can be detected in oropharyngeal secretions. Short term (1 month) treatment with oral acyclovir, which inhibits EBV replication, results in loss of virus shedding from the oropharynx, but the virus persists in B cells. The goal of this study is to determine if EBV will no longer persist in B cells in patients treated with long term (20 month) oral valaciclovir (which is metabolized to acyclovir). Blood samples and throat washings will be obtained every three months from individuals who are receiving valaciclovir for treatment of genital herpes simplex virus infection. These samples will be analyzed for EBV DNA to determine if the level of EBV DNA declines or becomes negative with long term antiviral therapy. If the level of EBV DNA becomes undetectable in EBV-seropositive persons during the study, we will ask the patients to return twice a year for five years or if they develop symptoms of mononucleosis, so that EBV DNA in their blood and throat washings can be studied. Knowledge gained from this study should provide important insights into the mechanism of persistence of EBV infection. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |